PARIS, April 10, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX)
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.
TOULOUSE, France & LAKELAND, Mich., March 11, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced its 2023 full-year financial results as approved by the full Board of Directors and an update on the activity to date. The audit procedures on the consolidated financial statements have been completed. T